Determine Your Path Amidst the Huawei Storm!
The effects of export ban regulations on China’s Huawei by the US have begun to extend to global enterprises. It has been reported that the Trump administration is considering adding surveillance camera giant Hikvision and Dahua Technology, etc. to the list of companies under embargo. Together with additional sanctions and tariffs on China by the US, and the growing number of industries with concerns of having a negative impact on business performance, despite the Nikkei average stocks prices exceeding 21,400 points on 20/5 and 22/5, it dropped below 21,000 points on 24/5.
In addition to the political situation surrounding the increase in consumption tax, there is a focus on the trend of the Japanese economy. The real GDP (preliminary figures) for the Jan-Mar term announced on 20/5 is +0.5% compared to the previous term. As external demand includes the special factor of a sharp decline in imports, domestic demand has risen by 0.1% compared to the previous term. Although private consumption and capital investment are at a deficit, housing spending has increased by 1.1% and public investment has increased by 1.5%. Although the increase of 3.8% in machinery orders (except ships and electric power) compared to the previous month announced on 22/5 also appears to be good, in contrast to the decline of 11.4% in the manufacturing industry that is heavility reliant on exports, the non-manufacturing industries show an increase of 13.4% and there is a prominent increase in the construction, leasing, and transportation industries. Although there are still concerns of the sectors easily affected by export ban regulations and the manufacturing industry that is largely reliant on exports approaching a difficult period, there is a need to pay attention to the public investment-related which will easily benefit from the “decision of the National Resilience Annual Plan for 2019 (tentative name)” set for “end May ~ early June this year”, and the domestic demand-related with the cabinet’s decision on 14/12 regarding “triennial emergency measures to strengthen national resilience, disaster prevention and reduction,”. However, there is a need to note that in order to stably execute the budget for public investment, political stability is imperative.
With the the general meeting for stockholders season around the corner, it is also a period where we look out for stockholders’ proposals being carried out for low ROE stocks by investment funds, etc. The “Japanese Version of the Corporate Governance Code” which comprises of 5 fundamental rules including “dialogue with the stockholders”, was officially announced on 6/2015, and on 6/2018, revisions such as, “to accurately grasp one’s company’s capital cost when drawing up and officially announcing management strategies and plans”, and “to disclose the policies and way of thinking, etc. involving cuts on cross-held stocks (listed stocks)”, were carried out. The total amount of the stock buyback acquisition quota announced between 1/4-21/5 has increased by 93% (1.77 trillion yen) compared to the same period the previous year. Although this is not limited to the period prior to the general stockholders’ meetings, in order to meet the expectations of investors who want to plan an increase in ROE via “dialogue”, it is likely that listed enterprises are all the more expected to strengthen returns to stockholders that focus on stock buybacks.
In the 27/5 issue, we will be covering Chugai Pharmaceutical (4519), Enbio Holdings (6092), Giken (6289), Tamron (7740), MS&AD Insurance Group Holdings (8725) and Nitori Holdings (9843).
・Founded in 1925 and company was established in 1943. In 2002, company became a subsidiary of the Swiss Roche group. Carries out the research, development, manufacture, retail and import and export of pharmeceuticals. Is the leading company domestically for biomedicine and antibody drugs, and holds the top shares for domestic sales of antibody drugs and in the cancer area. Has acquired certification for biomedicine in 116 countries.
・For FY2019/12 results for 1Q (Jan-Mar) announced on 24/4, sales revenue increased by 4.7% to 154.288 billion yen compared to the same period the previous year, operating income increased by 20.2% to 46.094 billion yen, and net income increased by 25.6% to 35.031 billion yen. TECENTRIQ, their new product in the cancer field, and main products such as PERJETA and ALECENSA are steady. Export of ALECENSA and ACTEMRA for Roche have grown.
・For the company’s full year plan, sales revenue is expected to increase by 2.2% to 592.5 billion yen compared to the previous year, core operating income to increase by 9.7% to 143 billion yen, and core EPS to increase by 12.2% to 198 yen, with payout ratio at 48.5%. On 21/5, company announced the investment of 127.3 billion yen to build a research facility in Yokohama City. Company is consolidating their research function spread into 2 bases and is pursuing synergy.
・Established in 1999. In addition to their main businesses which are the soil contamination countermeasure business (investigation, purification work and risk consulting of soil contamination) and the brownfield revitalisation business (effective utilisation support for contaminated soil regions), company also engages in the natural energy business.
・For FY2019/3 results announced on 15/5, net sales increased by 2.1% to 8.563 billion yen compared to the previous period, operating income decreased by 19.5% to 633 million yen, and net income fell into the red with ▲150 million yen from the previous term’s 403 million yen. Although company has secured an increase in revenue, the record of a ▲496 million yen loss of withrdrawal from operations involving consolidated subsidiaries, in addition to development costs involved with the introduction of an in situ purification technology have added up.
・For FY2020/3 plan, net sales is expected to increase by 7.9% to 9.237 billion yen compared to the previous year, and operating income to increase by 32.7% to 840 million yen. In China, the Soil Pollution Prevention and Control Law was enforced on 1/2019, and due to growing risks of a suspension in operations due to environmental regulations, their number of consulting orders increased from 11 cases within 4-12/2018 to 25 cases within 1-3/2019. In the midst of the US-China friction escalating, we can look forward to the increase in their number of orders from firms planning to reduce risk from Chinese businesses.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
